Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Recursion Pharmaceuticals
RXRX
Recursion Pharmaceuticals
High R&D Burn And Regulatory Hurdles Will Cripple Future Value
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
07 Aug 25
Updated
10 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$3.00
92.3% overvalued
intrinsic discount
10 Aug
US$5.77
Loading
1Y
-14.4%
7D
7.6%
Author's Valuation
US$3.0
92.3% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$3.0
92.3% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-649m
88m
2019
2021
2023
2025
2027
2028
Revenue US$88.4m
Earnings US$12.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
40.23%
Biotech revenue growth rate
12.85%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$12.48m
Earnings '28
x
155.72x
PE Ratio '28
=
US$1.94b
Market Cap '28
US$1.94b
Market Cap '28
/
532.48m
No. shares '28
=
US$3.65
Share Price '28
US$3.65
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$3.00
Fair Value '25
